samedan logo

 
 
spacer
home > ebr > spring 2003 > assessing the safety of inhaled biopharmaceuticals - current issues and recent developments
PUBLICATIONS
European Biopharmaceutical Review

Assessing the Safety of Inhaled Biopharmaceuticals - Current Issues and Recent Developments

It has long been recognised that inhalation is a very efficient means of introducing foreign substances into the body. As long as 500 years ago, Leonardo da Vinci realised that inhaled dust could cause lung pathology and so annotated one of his anatomical drawings of lungs - in his characteristic mirror writing - "polvere fa danno" or "dust causes damage".

The importance of inhalation as a route of exposure to injurious substances has long been recognised. For example ...


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Colin J Hardy, Director of Inhalation Studies at Huntingdon Life Sciences

Dr Colin J Hardy has over 30 years' experience in the safety assessment of inhaled pharmaceutical products. His first degree was in Biological Sciences, specialising in respiratory physiology, and his Doctorate was awarded for work on the effects of inhaled fibres.

Dr Hardy subsequently specialised in lung function testing in laboratory animals before moving into the wider field of inhalation safety assessment. He is currently Director of Inhalation Studies at Huntingdon Life Sciences.

spacer
Dr Colin J Hardy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Partners with Propeller Health to Gather Accurate Data on Asthma and COPD Medication Use

Philadelphia, PA – January 07, 2020: Signant Health announced today a partnership to connect TrialMax®, the industry-leading electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement